S. Edgerton

发表

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

A. Thor, B. Jacobsen, D. Cittelly, 2014, Breast Cancer Research.

Downregulation of miR-342 is associated with tamoxifen resistant breast tumors

P. M. Das, A. Thor, D. Cittelly, 2010, Molecular Cancer.

Metformin Enhances Trastuzumab Efficacy and Overcomes Resistance in HER2 Type Breast Cancer Cells.

F. Esteva, A. Thor, Bolin Liu, 2009 .

Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

E. Kawasaki, B. Mayall, A. Thor, 1992, Journal of the National Cancer Institute.

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.

D A Berry, D. Berry, L. Norton, 1998, Journal of the National Cancer Institute.

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer

Xiaoping Yang, A. Thor, Bolin Liu, 2013, Breast Cancer Research.

p53 gene mutations and protein accumulation in human ovarian cancer.

A. Thor, D. Bell, D. Yandell, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Characterization and chromosomal instability of novel derived cell lines from a wt-erbB-2 transgenic mouse model.

F. Waldman, G. Magrane, A. Thor, 2003, Carcinogenesis.

Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up.

S. Skates, A. Thor, H. Fingert, 1989, Cancer research.

pS2 expression and response to hormonal therapy in patients with advanced breast cancer.

P. Chambon, A. Thor, M. Rio, 1991, Cancer research.

COMMENT ON: TUMOR ANGIOGENESIS AS A PROGNOSTIC ASSAY FOR INVASIVE DUCTAL BREAST CARCINOMA. AUTHORS' REPLY

K. Chew, B. Ljung, S. Fox, 1995 .

pS2 expression in primary breast carcinomas: Relationship to clinical and histological features and survival

A. Thor, W. Wood, M. Stracher, 2005, Breast Cancer Research and Treatment.

Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells

A. Thor, Bolin Liu, Harry Lee, 2018, Scientific Reports.

p53 Inactivation Upregulates p73 Expression through E2F-1 Mediated Transcription

T. Sakai, A. Thor, S. Anant, 2012, PloS one.

Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma.

K. Chew, B. Ljung, B. Mayall, 1995, Journal of the National Cancer Institute.

Monoclonal antibodies reactive with human breast or ovarian carcinoma: in vivo applications.

A. Thor, S. Edgerton, Ann D. Thor, 1989, Seminars in nuclear medicine.

Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice.

A. Thor, Bolin Liu, Xiaohe Yang, 2003, Cancer research.

Stress response protein (srp-27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations.

C. Benz, B. Mayall, A. Thor, 1991, Journal of the National Cancer Institute.

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

E. Perez, G. Sledge, Molin Wang, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A comparison between DASL and Affymetrix on probing the whole-transcriptome

G. Sledge, B. Leyland-Jones, Jenny C. Chang, 2016 .

Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells

P. M. Das, A. Thor, S. Edgerton, 2010, Oncogene.

Biospecimen Banking, Standardization, and Lessons Learned from the Cancer and Leukemia Group B Pathology Coordinating Office

S. Jewell, R. Schilsky, L. Dressler, 2005 .

Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer

D. Gao, V. Borges, T. Lyons, 2013, Breast Cancer Research and Treatment.

The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer

A. Thor, P. Kabos, S. Anderson, 2017, Hormones and Cancer.

Metformin Accumulation Correlates with Organic Cation Transporter 2 Protein Expression and Predicts Mammary Tumor Regression In Vivo

M. C. Rudolph, A. Thor, S. Anderson, 2017, Cancer Prevention Research.

Activation of cancerous inhibitor of PP2A (CIP2A) contributes to lapatinib resistance through induction of CIP2A-Akt feedback loop in ErbB2-positive breast cancer cells

Bolin Liu, Ming Zhao, Ying Xing, 2017, Oncotarget.

pS2 protein and steroid hormone receptors in invasive breast carcinomas

F. Koerner, S. Edgerton, L. Schwartz, 1992, International journal of cancer.

A Modification of the Aldehyde Fuchsin and Orcein Stains for Hepatitis B Surface Antigen in Tissue and a Proposed Chemical Mechanism

S. Edgerton, J. Fredenburgh, A. E. Parker, 1978 .

Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling

D. Gao, A. Thor, C. Ambrosone, 2014, Breast Cancer Research.

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

Bolin Liu, A. Thor, Bolin Liu, 2009, Cell cycle.

Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer.

A. Thor, D. Moore, S. Edgerton, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Perinucleolar compartment prevalence has an independent prognostic value for breast cancer.

Sui Huang, R. Nayar, A. Thor, 2005, Cancer research.

Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptor‐positive breast cancer

P. Kabos, C. Sartorius, S. Sams, 2021, Molecular carcinogenesis.

Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: A comparative study

D. Louis, A. Thor, E. Hedley‐Whyte, 2004, Acta Neuropathologica.

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

A. Thor, Bolin Liu, S. Edgerton, 2009, Cell cycle.

Evaluation of in vitro bromodeoxyuridine labeling of breast carcinomas with the use of a commercial kit.

B. Lloveras, A. Thor, S. Edgerton, 1991, American journal of clinical pathology.

Glucose promotes breast cancer aggression and reduces metformin efficacy

A. Thor, S. Anderson, Bolin Liu, 2013, Cell cycle.

Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures

J. Harrell, P. Kabos, C. Sartorius, 2012, Breast Cancer Research and Treatment.

The erbB3- and IGF-1 receptor-initiated signaling pathways exhibit distinct effects on lapatinib sensitivity against trastuzumab-resistant breast cancer cells

A. Thor, Zhiming He, Bolin Liu, 2015, Oncotarget.

Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions

A. Thor, Bolin Liu, Xiaohe Yang, 2011, Cell cycle.

Invasive micropapillary carcinoma of the breast is associated with chromosome 8 abnormalities detected by comparative genomic hybridization.

S. Devries, F. Waldman, A. Thor, 2002, Human pathology.

FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.

Austin E. Gillen, M. Morrow, A. Thor, 2018, JCI insight.

Invasive micropapillary carcinoma of the breast: A prognostic study☆

A. Thor, D. Moore, S. Edgerton, 1999 .

p21WAF1/CIP1 Expression in breast cancers: associations with p53 and outcome

A. Thor, S. Edgerton, Qiuju Shi, 2000, Breast Cancer Research and Treatment.

Metformin attenuates transforming growth factor beta (TGF-β) mediated oncogenesis in mesenchymal stem-like/claudin-low triple negative breast cancer

A. Thor, J. Harrell, Bolin Liu, 2016, Cell cycle.

Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers

M. Lucia, A. Thor, S. Fosmire, 2016, Oncotarget.

Metformin Selectively Targets Tumor-Initiating Cells in ErbB2-Overexpressing Breast Cancer Models

A. Thor, Bolin Liu, Xiaohe Yang, 2013, Cancer Prevention Research.

Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.

C. Benz, A. Thor, D. Stern, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cells

A. Thor, Bolin Liu, Xiaohe Yang, 2007, International journal of cancer.

Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.

John Calvin Reed, S. Krajewski, M. Krajewska, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers.

D. Kwiatkowski, A. Thor, D. Moore, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

p53 mutations in benign breast tissue.

R. Millikan, L. Melton, B. Hulka, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases

Austin E. Gillen, A. Thor, B. Jacobsen, 2017, Front. Oncol..

HER2 and response to paclitaxel in node-positive breast cancer.

Larry Norton, James N Ingle, Matthew J Ellis, 2007, The New England journal of medicine.

Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers

A. Thor, Bolin Liu, S. Edgerton, 2012, Cell cycle.

Metformin-Induced Killing of Triple-Negative Breast Cancer Cells Is Mediated by Reduction in Fatty Acid Synthase via miRNA-193b

A. Thor, S. Anderson, E. Howe, 2014, Hormones and Cancer.

p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)

D. Berry, M. Ellis, E. Winer, 2011, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine p 53 Expression in Node-Positive Breast Cancer Patients : Results from the Cancer and Leukemia Group B 9344 Trial ( 159905 )

D. Berry, M. Ellis, E. Winer, 2011 .

Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer.

A. Thor, D. Moore, S. Edgerton, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to radiation therapy.

A. Thor, S. Edgerton, Xiao He Yang, 2005, International journal of oncology.

Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.

A. Thor, S. Edgerton, F. Jones, 2009, The American journal of pathology.

Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.

A. Thor, Zhiming He, Bolin Liu, 2015, International journal of clinical and experimental pathology.

Age-associated biomarker profiles of human breast cancer.

C. Benz, A. Thor, D. Moore, 2002, The international journal of biochemistry & cell biology.

PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) IN HUMAN NERVOUS SYSTEM TUMORS: 34

D. Louis, A. Thor, S. Edgerton, 1990 .

The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.

A. Thor, Rakesh Kumar, S. Edgerton, 2008, Cancer research.

HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer

K. Chew, B. Ljung, C. Benz, 1997, Oncogene.

Caspase-3 mediated feedback activation of apical caspases in doxorubicin and TNF-α induced apoptosis

A. Thor, Xiaohe Yang, S. Edgerton, 2006, Apoptosis.

Genistein induces enhanced growth promotion in ER-positive/erbB-2-overexpressing breast cancers by ER-erbB-2 cross talk and p27/kip1 downregulation.

A. Thor, Bolin Liu, Xiaohe Yang, 2010, Carcinogenesis.

Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients

M. Lucia, A. van Bokhoven, S. Edgerton, 2019, Journal of Immunotherapy for Cancer.

Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

D. Berry, L. Norton, L. Dressler, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of Cathepsin D expression in breast cancer: immunohistochemical assessment and correlation with radiometric assay.

C. Benz, A. Thor, D. Moore, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR+HER2+ breast cancer patients

A. Thor, A. Gutierrez-Hartmann, S. Edgerton, 2020, Breast Cancer Research and Treatment.

erbB-2 (HER-2) and Breast Cancer Progression

D. Merkel, A. Thor, D. Moore, 2003, Applied immunohistochemistry & molecular morphology : AIMM.

Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.

A. Thor, D. Stern, S. Whalen, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention.

A. Thor, Bolin Liu, Xiaohe Yang, 2005, Cancer research.

ErbB-2 protein in sera and tumors of breast cancer patients

R. Simmons, H. Cody, A. Thor, 1998, Breast Cancer Research and Treatment.

Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells

A. Thor, Bolin Liu, Xiaohe Yang, 2005, Breast Cancer Research.

Estrogenic Promotion of ErbB2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB3 Signaling

A. Thor, Bolin Liu, Xiaohe Yang, 2009, Molecular Cancer Research.

Estrogenic Promotion of ErbB 2 Tyrosine Kinase Activity in Mammary Tumor Cells Requires Activation of ErbB 3 Signaling

A. Thor, Bolin Liu, Xiaohe Yang, 2009 .

Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor–Positive Breast Cancers

A. Tan, A. Thor, B. Jacobsen, 2020, Clinical Cancer Research.

FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation.

M. Morrow, A. Thor, B. Jacobsen, 2018, JCI insight.

Metformin Selectively Targets Tumor-Initiating Cells in ErbB2-Overexpressing Breast Cancer Models

A. Thor, Bolin Liu, Xiaohe Yang, 2013, Cancer Prevention Research.

Gelsolin as a negative prognostic factor and effector of motility in erbB-2-positive epidermal growth factor receptor-positive breast cancers.

S. Edgerton, Ann D. Thor, Shuqing Liu, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.

A. Thor, Zhiming He, Bolin Liu, 2015, International journal of clinical and experimental pathology.

Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer.

S. Edgerton, Ann D. Thor, Shuqing Liu, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)

D. Berry, M. Ellis, E. Winer, 2011, Clinical Cancer Research.

p 53 Expression in Node Positive Breast Cancer Patients : Results from the Cancer and Leukemia Group B ( CALGB ) 9344 Trial ( 159905 )

C. Hudis, D. Cowan, I. Bleiweiss, 2011 .

Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast Cancer.

S. Edgerton, Ann D. Thor, Reema S Wahdan-Alaswad, 2023, Cell cycle.

Abstract P1-05-01: Characterization of human postpartum breast involution: Implications for young women’s breast cancer

D. Gao, A. Thor, C. Ambrosone, 2013 .